TORONTO, March 27, 2007 (PRIME NEWSWIRE) -- Millennium Biotechnologies Group, Inc. (OTCBB:MBTG) announces today that it signed a letter of intent with a Canadian subsidiary of an international pharmaceutical company on terms for the distribution and marketing of its Resurgex product line for the Canadian oncology market.
Under the terms of reference, a distribution agreement will be formalized where Millennium will grant exclusive marketing rights to this pharmaceutical company to distribute and market its line of Resurgex products for cancer patients in Canada.
"This is a distribution and marketing initiative that will make Resurgex available to Canadian patients, and enhance our position in North America. The overwhelming endorsement of Resurgex products by oncology practitioners in the U.S. is the catalyst that created this Canadian distribution opportunity," according to Jerry Swon, Sr., President of Millennium Biotechnologies Group, Inc.
Resurgex Select(tm), which is making inroads in the oncology marketplace, has just been issued a United States Composition Patent for the proprietary formula, as well as a registered trademark. Resurgex Select(tm) was developed to provide a superior source of high-quality calories as opposed to the corn oil and corn syrup-laden products that are found in the marketplace. As with the previous patent issued for Resurgex(r), this additional patent serves to protect the intellectual property of Millennium's new addition to the Resurgex(r) family of products
About Millennium Biotechnologies, Inc.: Millennium Biotechnologies, Inc. is a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements. The company's flagship products, Resurgex(r), Resurgex Plus(r), and Resurgex Select(r), are designed to assist in reducing fatigue and oxidative stress, maintaining lean muscle and immune support in immunocompromised conditions.
Millennium Biotechnologies, Inc. is a wholly owned subsidiary of Millennium Biotechnologies Group, Inc., a publicly-traded company (OTCBB:MBTG). For more information about Millennium Biotechnologies, please contact Frank Guarino, Chief Financial Officer, at fguarino@milbiotech.com or call (908) 604-2500. For more information about the Resurgex line of products visit www.resurgex.com.
This release includes certain forward-looking information that is based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of Resurgex and Resurgex Plus and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially form those anticipated in such forward-looking statements even if experience or future changes make it clear the any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.